Balance Sheet as at 31 March 2017		CHF	(₹ in thousand)	CHF	(₹ in thousand)	CHF	(₹ in thousand)
	Notes	A	s at	A	As at	Α	s at
		31-N	1аг-17	31-1	Mar-16	1-A	pr-15
ASSETS							
Current assets							
Financial assets							
i, Cash and cash equivalents	1			3.5	I E	29,711	1,909
ii. Other financial assets	2	3,099	201	5,142	355		
Total current assets		3,099	201	5,142	355	29,711	1,909
Total assets	=	3,099	201	5,142	355	29,711	1,909
EQUITY AND LIABILITIES							
Equity							
Equity share capital	3(a)	100,000	4,697	100,000	4,697	100,000	4,697
Other equity	3(b)	(120,085)	(5,999)	(94,858)	(4,342)	(87,336)	(3,883
Total equity	_	(20,085)	(1,302)	5,142	355	12,664	814
LIABILITIES							
Current liabilities							
Financial liabilities							
ii. Trade payables	4	23,184	1,503	-	- 12	17,047	1,095
Total current liabilities	).—	23,184	1,503	-	92	17,047	1,095
Fotal liabilities	_	23,184	1,503	551	S (55)	17,047	1,095
Total equity and liabilities	-	3,099	201	5,142	355	29,711	1,909

PRAKASH C BISHT CFO (LSI) & Sr. VP (Group Accounts)

Place: Noida Date: 22 April, 2017

## Jubilant Life Sciences Switzerland AG Statement of Profit and Loss for the year ended 31 March 2017

		CHF	(₹ in thousand)	CHF	_(₹ in thousand)
	Notes		year ended -Mar-17		year ended Mar-16
Revenue	Notes	31-	-1 <b>v1a1-1</b> /	31-	-1v1a1-10
Other income		1			
Total income		2	-	120	2
Expenses					
Other expenses	5	25,227	1,707	7,522	505
Total expenses	_	25,227	1,707	7,522	505
Loss before tax		(25,227)	(1,707)	(7,522)	(505)
Tax expense	-				
- Current tax			-	14	ű.
- Deferred tax charge		- 4	120	120	25
Total tax expense	-	~	380	(2)	
Loss for the year	**	(25,227)	(1,707)	(7,522)	(505)
Other comprehensive income	_				
Items that will be reclassified to profit or loss					
Exchange differences on translation of foreign operations			50		46
Other comprehensive income for the year, net of tax	-	-	50	(*)	46
Total comprehensive income for the year		(25,227)	(1,657)	(7,522)	(459)

## PRAKASH C BISHT CFO (LSI) & Sr. VP (Group Accounts)

Place: Noida Date: 22 April, 2017

### Jubilant Life Sciences Switzerland AG Statement of Cash Flows for the year ended 31 March 2017

	CHF	(₹ in thousand)	CHF	(₹ in thousand)	
		year ended Mar-17	For the year ended 31-Mar-16		
A. Cash flow from operating activities					
Net loss before tax	(25,227)	(1,707)	(7,522)	(505)	
Adjustments:					
Irrecoverable advances written off	•	120	(3,404)	(228)	
	-	(#)	(3,404)	(228)	
Operating cash flow before working capital changes	(25,227)	(1,707)	(10,926)	(733)	
Decrease/(increase) in trade receivable and other financial assets	2,043	139	(5,142)	(345)	
Increase/(decrease) in trade payables, provisions and other liabilities	23,184	1,573	(13,643)	(915)	
Cash generated from operations		5	(29,711)	(1,993)	
Income tax and wealth tax paid (net of refund)		(#)	32	2	
Net cash generated from operating activities		5	(29,711)	(1,993)	
B. Cash flow from investing activities					
Net cash used in investing activities		(2)	2	3	
C. Cash flow from financing activities					
Net cash used in financing activities	- 4	72:			
D. Effect of exchange rate changes		(5)	39	84	
Net decrease in cash and cash equivalents (A+B+C+D)	2	43	(29,711)	(1,909)	
Add: cash and cash equivalents at the beginning of year			29,711	1,909	
Cash and cash equivalents at the end of the year	-	(40)		9	

PRAKASH C BISHT CFO (LSI) & Sr. VP (Group Accounts)

Place: Noida Date: 22 April, 2017

Notes to the financial statements for the year ended 31 March 2017

## 1. Cash and cash equivalents

	CHF	(₹ in thousand)	CHF	(₹ in thousand)	CHF	(₹ in thousand)
		As at		As at		As at
	31 1	March 2017	31 N	March 2016	01 A	pril 2015
Balances with banks						
- in current accounts		1 (6)	$\times$	3.0	29,711	1,909
Total cash and cash equivalents		-	-		29,711	1,909

### 2. Other financial assets

CHF	(₹ in thousand)	CHF	(₹ in thousand)	CHF	(₹ in thousand)
As	at		As at		As at
31 March 2017		31 March 2016		01 April 2015	
Cur	rent	C	urrent		Current
3,099	201	5,142	355		/5:
3,099	201	5,142	355	2	
	As 31 Mar Cur 3,099	As at 31 March 2017 Current 3,099 201	As at  31 March 2017 31 M  Current C  3,099 201 5,142	As at As at  31 March 2017 31 March 2016  Current Current  3,099 201 5,142 355	As at As at  31 March 2017 31 March 2016 01 .  Current Current 0  3,099 201 5,142 355 -

Notes to the financial statements for the year ended 31 March 2017

#### 3 (a) Equity share capital

- (.,	CHF	9	(₹ in thousand)	CI	HF	(7 in thousand)	CHF	(₹ in thousand)
		Asa	t ·		As	at		s at
		31 March	2017		31 Mar	ch 2016	01 Ar	ril 2015
Authorised Equity share capital 100,000 Equity Shares of CHF I each (31 March 2016 and 01 April 2015 - 100,000 shares of CHF I each)		.*	,	œ	(#X	: :	9 <u>at</u>	
				+	3.40			
Issued, Subscribed and Paid up Equity share capital 100,000 shares (31 March 2016 and 01 April 2015: 100,000 shares) of CHF 1 each		100,000	4,69	7	100,000	4,697	100,000	4,697
	9	100,000	4,6	97	100,000	4,697	100,000	4,69
Movements in equity share capital	2							
	No. of shares	1	(₹ in thousand)		lo, of shares	(₹ in thousand)	No. of shares	(₹ in thousand)
At the commencement of the year		100,000	4,69	77	100,000	4,697	100,000	4,697
Additions during the year		100.000	140	7	100 000	4 (07	100,000	4.607
At the end of the year		100,000	4,69	/	100,000	4,697	100,000	4,697

#### Terms and rights attached to equity shares

The Company has only class of shares referred to as equity shares having par value of CHF I each, Each holder of equity shares is entitled to one vote per share.

In the event of liquidation of the Company, the holders of equity shares will be entitled to receive any of the remaining assets of the Company, after distribution of all preferential amounts. However, no preferential liabilities exist currently. The distribution will be in proportion to the number of equity shares held by the shareholders.

	As at		As	at	As	at
	31 March 2017		31 March 2016		01 Apri	l 2015
	No. of shares	% holding	No. of shares	% holding	No. of shares	% helding
Jubilant Pharma Pte Ltd - The Holding Company			100,000	100,00%	100,000	100,00%
Jubilant Life Sciences International Pte Ltd - The Holding Company	100,000	100%	-	•	-	-

46

(4,342)

#### 3 (b) Other Equity

As at 31 March 2016

	Reserves and Surplus			
	Retained earnings	Total		
As at 1 April 2015	(87,336)	(87,336)		
Profit for the year	(7,522)	(7,522)		
Additions during the year				
Total comprehensive income for the year	(7,522)	(7,522)		
As at 31 March 2016	(94,858)	(94,858)		

	Reserves and Surplus			
	Retained earnings	Total		
As at 1 April 2016	(94,858)	(94,858)		
Profit for the year	(25,227)	(25,227)		
Total comprehensive income for the year	(25,227)	(25,227)		
As at 31 March 2017	(120,085)	(120,085)		

(₹ in thousand) Other comprehensive Total Reserves and Surplus Foreign currency Retained earnings translation reserve As at 1 April 2015 Profit for the year (3,883) (505) (3,883) (505) Other comprehensive income 46 46 Additions during the year

Total comprehensive income for the year (459) (505) 46

(4,388)

	Reserves and Surplus	Other comprehensive income	Total	
	Retained earnings	Foreign currency translation reserve		
As at 1 April 2016	(4,388)	46		(4,342)
Profit for the year	(1,707)			(1,707)
Other comprehensive income		50		50
Total comprehensive income for the year	(1,707)	50		(1,657)
As at 31 March 2017	(6,095)	96		(5,999)

Notes to the financial statements for the year ended 31 March 2017

## 4. Trade payables

	CHF	(₹ in thousand)	CHF	(₹ in thousand)	CHF	(₹ in thousand)
•	4	As at		As at	Α	rs at
16	31 1	March 2017	31 N	farch 2016	01 A <sub>I</sub>	oril 2015
Current Trade payables	23,18	4 1,503	<b>19</b>	a	17,047	1,095
Total trade payables	23,18	4 1,503		:=	17,047	1,095

Notes to the financial statements for the year ended 31 March 2017

# 5. Other expenses

	CHF	(₹ in thousand)	CHF	(₹ in thousand)
Particulars	For th	e year ended	For the	year ended
	31 M	Iarch 2017	31 M	larch 2016
Rent	1,620	110	1,215	81
Legal and professional fees	23,286	1,575	7,231	489
Bank charges	2	=	2,480	166
Irrecoverable advances written off			(3,404)	(231)
Foreign Exchange Gain/Loss	321	22		
Total other expenses	25,227	1,707	7,522	505